Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib
Multiple myeloma (MM) is a neoplastic lymphoproliferative disorder characterized by uncontrolled monoclonal plasma cell proliferation. Among different isotypes of MM, immunoglobulin D (IgD) MM is very rare, representing only 1 to 2% of all isotypes. Chronic myelogenous leukemia (CML) is a neoplastic...
Main Authors: | Naveed Ali, Peter V. Pickens, Herbert E. Auerbach |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2016-03-01
|
Series: | Hematology Reports |
Subjects: | |
Online Access: | http://www.pagepress.org/journals/index.php/hr/article/view/6295 |
Similar Items
-
TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
by: Mateja Grat, et al.
Published: (2004-12-01) -
Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01) -
The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011-03-01) -
Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01) -
Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy
by: Ćojbašić Irena, et al.
Published: (2010-01-01)